Drug · CHEMBL11

IMIPRAMINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. IMIPRAMINE. Drugs and targets, record CHEMBL11. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL11

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: IMIPRAMINE; ChEMBL
ChEMBL ID: CHEMBL11; ChEMBL
Type: Small molecule; ChEMBL
Other names: Antideprin, Berkomine, Cristalia, Imipramina, Melipramine, NSC-169866, ORG-2463, Sermonil, Trimipramine maleate impurity, imipramine-; ChEMBL
Other form: IMIPRAMINE HYDROCHLORIDE, CHEMBL1692; Drugs and targets
Other form: IMIPRAMINE PAMOATE, CHEMBL3989845; Drugs and targets
DrugBank: DB00458; DrugBank
InChIKey: BCGWQEUPMDMJNV-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 2 of its 18 diseases, from ATC and TTD; Open Targets

Targets2

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
SLC6A2	Sodium-dependent noradrenaline transporter	Norepinephrine transporter inhibitor	INHIBITOR	https://conductscience.org/library/genes/6530
SLC6A4	Sodium-dependent serotonin transporter	Serotonin transporter inhibitor	INHIBITOR	https://conductscience.org/library/genes/6532

Source ChEMBL

Diseases18

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
major depressive disorder	Approval	ATC and TTD	7	5	https://conductscience.org/library/drugs?q=MONDO_0002009
depressive disorder	Approval	TTD	3	2	https://conductscience.org/library/drugs?q=MONDO_0002050
Stress urinary incontinence	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0010992
fibromyalgia	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005546
ventricular fibrillation	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0000190
Cutaneous photosensitivity	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0000992
Low back pain	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0003419
Sudden death	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0001699
actinic keratosis	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005173
gastroesophageal reflux disease	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0007186

1 to 10 of 18Source Open Targets

See all 18 diseases

Trials33

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01028014	Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters		56	2011-09-05	imipramine	Its name	ClinicalTrials.gov
NCT00296725	Dichotic Listening as a Predictor of Medication Response in Depression	Phase 1/2	25	2019-05-15	imipramine	Its name	ClinicalTrials.gov
NCT00404755	Dichotic Listening as a Predictor of Medication Response in Depression	Phase 4	17	2018-03-15	imipramine	Its name	ClinicalTrials.gov
NCT06778824	Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.		610		imipramine	Its name	ClinicalTrials.gov
NCT06497647	New Treatment for Nocturnal Enuresis in Children		450		imipramine	Its name	ClinicalTrials.gov
NCT02374567	Pharmacovigilance in Gerontopsychiatric Patients	Phase 3	407		imipramine	Its name	ClinicalTrials.gov
NCT00004834	Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder		326		imipramine	Its name	ClinicalTrials.gov
NCT00227955	Comparing Various Treatments for Achieving and Maintaining Remission of Depression	Phase 4	200		imipramine	Its name	ClinicalTrials.gov
NCT01179828	Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)	Phase 3	150		imipramine	Its name	ClinicalTrials.gov
NCT01518634	Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome	Phase 2	138		imipramine	Its name	ClinicalTrials.gov

1 to 10 of 33

See all 33 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Fluoxetine vs Imipramine: Number of Participants With Positive Response as Assessed by the Clinical Global Impression -Global Improvement Scale (CGI-I)	7 of 17	4 of 8	25	NCT00296725	Trial comparisons
Fluoxetine vs Imipramine: deaths from any cause	0 of 17	0 of 8	25	NCT00296725	Trial comparisons
Fluoxetine vs Imipramine: serious adverse events	0 of 17	0 of 8	25	NCT00296725	Trial comparisons

Papers from its trials14

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28408193	RESULT	1	PubMed
19380256	RESULT	1	PubMed
18654615	RESULT	1	PubMed
16616268	RESULT	1	PubMed
16215338	RESULT	1	PubMed
40266345	DERIVED	1	PubMed
37155164	DERIVED	1	PubMed
36918228	DERIVED	1	PubMed
33857917	DERIVED	1	PubMed
30361080	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL11

GET https://conductscience.org/api/drugs/v1/CHEMBL11/trials?page=2

API reference For AI assistants